Discover 1,169 paid clinical trials in Montreal, Quebec. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,169
Active & Responsive
A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants
for
Healthy Volunteers
Location: Mount Royal
Sponsor: argenx
Sex: All
Age: 18 - 65
Code: NCT07612020
Phase 1, Recruiting
Active & Responsive
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
for
Breast Neoplasms
Location: Montreal, Quebec, Boston MA, Nyack NY, Stamford CT,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06312176
Phase 3, Recruiting
Active & Responsive
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
for
Primary Myelofibrosis (PMF),
Location: Montreal, Albany NY, New Haven CT, New York NY,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18+
Code: NCT07357727
Phase 3, Recruiting
Active & Responsive
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
for
PIK3CA Mutation, HER2- Negative Breast Cancer,
Location: Montreal, Ottawa, Boston MA, New Haven CT, Toronto,
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06982521
Phase 3, Recruiting
Active & Responsive
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
for
Solid Tumor
Location: Montreal, Boston MA, New Haven CT, Toronto,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT06619587
Phase 1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment